Hints and tips:
Related Special Reports
...In its pharmaceutical division, Bayer had to abandon a late-stage trial for its most promising drug last year, meaning it has only a few potential blockbusters left in its pipeline: treatments for prostate...
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...It is hard to see how he can climb out of the morass without selling or spinning off the company’s consumer health division, despite Bayer long resisting calls for a break-up....
...If selling equity is really off the table, a sale or spin-off of at least one division — namely consumer health — remains the only way to meaningfully tackle Bayer’s debt woes....
...“The public debate about Bayer’s future was too narrowly focused on a break-up,” he said, adding that Anderson was right to address Bayer’s underlying problems....
...The Texas native, who joined Bayer last summer after his predecessor Werner Baumann was pushed out, argued that Bayer first needed to focus on fixing its financial and operating problems, warning that the...
...Alongside Ubben, Bayer nominated Nancy Simonian, the former CEO of US biotech company Syros Pharmaceuticals, and Lori Schechter, the former general counsel of US healthcare group McKesson, to join its supervisory...
...Bayer paid a dividend of €2.40 for 2022. Analysts had expected Bayer to pay a dividend of €1.92 per share for 2023, a far more modest cut....
...This follows GSK’s spin-off of its consumer health division Haleon, and the strong performance of its vaccines unit, including Arexvy, a new vaccine for respiratory syncytial virus that reached blockbuster...
...more diverse organisation, with broad expertise and a core focus on improving patient outcomes, we are confident we will be able to further solidify [intravascular lithotripsy] as the global standard of care...
...So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years....
...Cuban is targeting the 38 per cent of private sector employers who self-insure at least one of their health plans....
...that Roundup causes cancer, which Bayer denies....
...The company, which is best known for creating aspirin more than a century ago, is exploring whether to split off its crop sciences business or its consumer health division in an effort to appease disgruntled...
...The consumer health division has a value roughly half that. That would raise questions about the independence of a business that is small by industry standards....
...Bayer last week abandoned a trial of blood-thinner asundexian after it did not work as hoped to treat heart disease....
...AstraZeneca’s transformation is the sort of turnaround that others in the sector, such as Germany’s Bayer, need to replicate....
...Analysts expect a sale of the consumer health unit, which makes over-the-counter drugs and is estimated to be worth about €18bn, is the most likely scenario....
...Pfizer and BioNTech will dispute Moderna’s ability to withdraw the pledge when it did, given the World Health Organization did not declare the end of the “global health emergency” until March 2023....
...“It was one of the most epic episodes ever in pharmaceuticals history: you got an accelerated approval of a product that didn’t have a completed phase 3 trial....
...AstraZeneca has acquired oncology biotech Fusion Pharmaceuticals for $2.4bn to build its expertise and challenge Swiss company Novartis in the developing field of a more targeted form of radiotherapy....
Admonitions about staff trading in their employer’s shares may now need to be broadened
...and Social Care said: “Concessionary prices can arise for various reasons and cannot be linked to shortages.”...
...If we as a society are serious about women’s rights, then pharmaceutical companies and the wider global health community must ensure that mothers in the 21st century have a better chance than Kaveri of bringing...
...Novavax is this year rolling out its second product: a malaria vaccine approved by the World Health Organization, which will help to grow its revenues from $531.4mn last year to a projected $854.2mn this...
International Edition